SCHEMBL95648

SCHEMBL95648

[CH2]c1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.60
HDAC1 Q13547 3/20 0.60
HDAC8 Q9BY41 3/20 0.60
HDAC3 O15379 2/20 0.57
HDAC4 P56524 2/20 0.57
HDAC7 Q8WUI4 2/20 0.57
HDAC2 Q92769 2/20 0.57
HDAC10 Q969S8 2/20 0.57
HDAC11 Q96DB2 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
HDAC9 Q9UKV0 2/20 0.57
HDAC5 Q9UQL6 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
TP53 P04637 2/20 0.56
MAPT P10636 2/20 0.55
DRD2 P14416 1/20 0.54
DRD3 P35462 1/20 0.54
KCNH2 Q12809 1/20 0.54
KIF11 P52732 1/20 0.54
RORC P51449 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28913958 0.88 KIF11 (0.69) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL7570513 0.86 FFAR4 (0.64) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL14601690 0.85 FFAR4 (0.68) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL18031172 0.85 HDAC1 (0.63) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL6756075 0.85 FFAR4 (0.68) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL7570765 0.85 CES1 (0.67) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL28570269 0.85 FFAR4 (0.60) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL7572608 0.84 KMT2A (0.61) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL94660 0.83 HDAC3 (0.60) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6026901 0.83 HDAC1 (0.65) FFAR4HDAC1HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB FFAR4 3769/4885HDAC1 476/4885HDAC8 1201/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 FFAR4 855/4885HDAC1 1814/4885HDAC8 3441/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 FFAR4 855/4885HDAC1 1814/4885HDAC8 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.